EP3581573A1 — Synthesis of a compound that modulates kinases
Assigned to Daiichi Sankyo Co Ltd · Expires 2019-12-18 · 6y expired
What this patent protects
The present disclosure provides a process for the preparation of crystalline Form C of Compound II:comprising:(1) adding Compound II to from about 0.4% v/v wet methyl tert-butyl ether (MTBE) to about 1.5% v/v wet MTBE to provide a reaction mixture;(2) refluxing the reaction mixtu…
USPTO Abstract
The present disclosure provides a process for the preparation of crystalline Form C of Compound II:comprising:(1) adding Compound II to from about 0.4% v/v wet methyl tert-butyl ether (MTBE) to about 1.5% v/v wet MTBE to provide a reaction mixture;(2) refluxing the reaction mixture;(3) cooling the reaction mixture to about room temperature; and(4) isolating the crystalline Form C of Compound II from the reaction mixture.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.